Cardiovascular complications in cystic fibrosis: A review of the literature
| Autor: | Edith T. Zemanick, T. Spencer Poore, Jennifer L. Taylor-Cousar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Cystic Fibrosis Sildenafil Cystic Fibrosis Transmembrane Conductance Regulator Disease Systemic inflammation Gastroenterology Cystic fibrosis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus Internal medicine medicine Humans Respiratory system biology business.industry Vascular disease respiratory system medicine.disease Cystic fibrosis transmembrane conductance regulator respiratory tract diseases 030104 developmental biology 030228 respiratory system chemistry Cardiovascular Diseases Pediatrics Perinatology and Child Health biology.protein medicine.symptom business |
| Zdroj: | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 21(1) |
| ISSN: | 1873-5010 |
| Popis: | Cystic fibrosis is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to dysfunction of the CFTR protein. CFTR dysfunction leads to disease in the respiratory and gastrointestinal systems. Disorders of the cardiovascular system in individuals with CF are usually attributed to secondary effects from progressive lung disease. However, CFTR has been localized to vascular endothelium and smooth muscle, suggesting that CFTR dysfunction may directly impact cardiovascular function. As treatments for CF improve and life-expectancy increases, the risk of vascular disease may increase in prevalence related to primary and secondary CFTR dysfunction, chronic systemic inflammation, nutritional health and hyperglycemia in individuals with CF related diabetes. Here we review the available literature on CF and the cardiovascular system, examining the secondary effects and evidence for direct CFTR dysfunction in the heart, aorta, pulmonary vessels, and vasculature, as well as future directions and treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect